Histone Deacetylase Inhibitors -- Epidrugs for Neurological Disorders
暫譯: 組蛋白去乙醯酶抑制劑 -- 神經疾病的表觀藥物
Ganai, Shabir Ahmad
相關主題
商品描述
This book provides an outline of epigenetics as a whole, while also specifically examining a range of epigenetic players, including histone acetyl transferases (HATs) and histone deacetylases (HDACs). It chiefly focuses on the emerging targets of HDACs and their implications for various neurological disorders, while also discussing the drawbacks of current therapeutic strategies, the classification of HDAC inhibitors, and their promising effects in connection with specific neurological disorders.
The book explores the potential use of these inhibitors as novel therapeutic agents, considers the current challenges involved in using them to tackle neurological complications, and offers a novel solution by designing isoform-selective inhibitors and employing combinatorial therapeutic strategies. Its final section, which explores future directions, elaborates on the possibility of enhancing HDAC inhibitors' therapeutic efficacy against various neurological complications.
商品描述(中文翻譯)
本書提供了表觀遺傳學的整體概述，同時具體檢視了一系列表觀遺傳學的參與者，包括組蛋白乙醯轉移酶（HATs）和組蛋白去乙醯酶（HDACs）。本書主要聚焦於HDACs的新興靶點及其對各種神經疾病的影響，同時討論當前治療策略的缺陷、HDAC抑制劑的分類，以及它們在特定神經疾病中的潛在效果。
本書探討了這些抑制劑作為新型治療劑的潛在用途，考慮了在使用它們應對神經併發症時所面臨的當前挑戰，並通過設計同種型選擇性抑制劑和採用組合治療策略提供了一種新解決方案。最後一部分探討了未來的方向，詳細說明了增強HDAC抑制劑對各種神經併發症的治療效果的可能性。
作者簡介
Dr. Shabir Ahmad Ganai is currently working as Assistant Professor Cum Junior Scientist, Division of Basic Sciences and Humanities, Faculty of Agriculture, SKUAST-Kashmir, Wadura, Sopore, 193201, Jammu & Kashmir, India. He has done his masters in Biochemistry from Bangalore University (2005-2007) and earned his Ph.D. from elite SASTRA University (2009-2014). Later, he did his post-doctorate from National Brain Research Centre, Haryana, India. He has also served as research fellow in SKUAST-Kashmir. His research interests are focused on understanding the modulations of the nuclear geometry and post-translational modifications during treatment with structurally distinct HDAC inhibitors. He has been actively involved in designing the target-selective inhibitors against Class II HDACs using various bioinformatics tools.
Dr. Shabir Ahmad Ganai has published more than 20 research articles and one editorial in high impact factor international Journals. He has also served as guest editor for a thematic issue (Epigenetics: A novel frontier for drug discovery) published by Current Medicinal Chemistry. In addition, he serves as a referee for many reputed international journals like Current Drug Targets, PLOS ONE and Medicinal Chemistry Research. He is an active member of many national and international societies including, The International Association of Therapeutic Drug Monitoring and Clinical Toxicology (IATDMCT).
作者簡介(中文翻譯)
Dr. Shabir Ahmad Ganai 目前擔任印度查謨和克什米爾州 SKUAST-Kashmir 農業學院基礎科學與人文學科部的助理教授兼初級科學家。他於班加羅爾大學獲得生物化學碩士學位（2005-2007），並在知名的 SASTRA 大學獲得博士學位（2009-2014）。之後，他在印度哈里亞納邦的國家腦研究中心進行了博士後研究。他還曾擔任 SKUAST-Kashmir 的研究員。他的研究興趣集中在理解核幾何的調節以及在使用結構上不同的 HDAC 抑制劑治療過程中的翻譯後修飾。他積極參與設計針對 II 類 HDAC 的靶向選擇性抑制劑，並使用各種生物資訊工具進行研究。
Dr. Shabir Ahmad Ganai 已在高影響因子的國際期刊上發表了超過 20 篇研究文章和一篇編輯文章。他還擔任了《當前藥物化學》發表的主題專刊（表觀遺傳學：藥物發現的新前沿）的客座編輯。此外，他還擔任多本知名國際期刊的審稿人，如《當前藥物靶點》、《PLOS ONE》和《藥物化學研究》。他是多個國內外學會的活躍成員，包括國際治療藥物監測與臨床毒理學協會（IATDMCT）。
